Transcription factor CEBPB inhibits the proliferation of osteosarcoma by regulating downstream target gene CLEC5A
- PMID: 31364785
- PMCID: PMC6868409
- DOI: 10.1002/jcla.22985
Transcription factor CEBPB inhibits the proliferation of osteosarcoma by regulating downstream target gene CLEC5A
Abstract
Objective: To screen the gene related to osteosarcoma (OS) metastasis and the molecular mechanism.
Methods: GEO database and R2 chip analysis platform were used to screen genes related to OS metastasis. UCSC gene browser was used to find the transcription factor (TF) of CLEC5A. The mRNA level and protein expression of CLEC5A in OS tissues and normal tissues were determined by RT-PCR and Western blotting, respectively. OS cell lines MG-63 were transfected with CEBPB recombinant plasmid. After transfection, the expression of CLEC5A in MG-63 cells was determined and the cell proliferation situation was determined by clone formation assay.
Results: Three genes CLEC5A, ALOX5AP, and RNASE3 were obtained, and CLEC5A has the highest correlation with OS. CLEC5A has screened the gene related to OS metastasis, and CEBPB can be taken as TF regulating downstream gene CLEC5A. CEBPB can regulate the downstream CLEC5A as transcription factor. The relative mRNA level and protein expression of CLEC5A in OS tissues were significantly higher than those in normal tissues. CLEC5A can prevent OS metastasis. Transfection of CEBPB increased the expression of CLEC5A in MG-63 cells and also inhibited the proliferation of OS.
Conclusion: CEBPB can inhibit the proliferation of OS cells via regulating the expression of CLEC5A.
Keywords: C-type lectin domain family 5; enhancer-binding protein beta; member A; osteosarcoma; proliferation; transcription factor.
© 2019 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals, Inc.
Conflict of interest statement
All of the authors have no conflict of interest in this research.
Figures





Similar articles
-
CLEC5A suppresses cell growth and metastasis via interfering with the calcineurin/NFATc1 signaling pathway in osteosarcoma.Exp Cell Res. 2025 Jul 15;450(2):114650. doi: 10.1016/j.yexcr.2025.114650. Epub 2025 Jun 14. Exp Cell Res. 2025. PMID: 40516779
-
C-type lectin domain family 5, member A (CLEC5A, MDL-1) promotes brain glioblastoma tumorigenesis by regulating PI3K/Akt signalling.Cell Prolif. 2019 May;52(3):e12584. doi: 10.1111/cpr.12584. Epub 2019 Mar 4. Cell Prolif. 2019. PMID: 30834619 Free PMC article.
-
MicroRNA-187 Inhibits Growth and Metastasis of Osteosarcoma by Downregulating S100A4.Cancer Invest. 2018 Jan 2;36(1):1-9. doi: 10.1080/07357907.2017.1415348. Epub 2018 Jan 5. Cancer Invest. 2018. PMID: 29303365
-
CLEC5A promotes the proliferation of gastric cancer cells by activating the PI3K/AKT/mTOR pathway.Biochem Biophys Res Commun. 2020 Apr 9;524(3):656-662. doi: 10.1016/j.bbrc.2019.10.122. Epub 2020 Feb 6. Biochem Biophys Res Commun. 2020. PMID: 32033754
-
Signature constructed by glycolysis-immune-related genes can predict the prognosis of osteosarcoma patients.Invest New Drugs. 2022 Aug;40(4):818-830. doi: 10.1007/s10637-022-01228-4. Epub 2022 Apr 18. Invest New Drugs. 2022. PMID: 35435626 Review.
Cited by
-
A Pan-Cancer Analysis Reveals CLEC5A as a Biomarker for Cancer Immunity and Prognosis.Front Immunol. 2022 Aug 1;13:831542. doi: 10.3389/fimmu.2022.831542. eCollection 2022. Front Immunol. 2022. PMID: 35979347 Free PMC article.
-
[Overexpression of CLEC5A inhibits cell proliferation and metastasis and reverses epithelial-mesenchymal transition in hepatocellular carcinoma].Nan Fang Yi Ke Da Xue Xue Bao. 2023 Jan 20;43(1):85-91. doi: 10.12122/j.issn.1673-4254.2023.01.11. Nan Fang Yi Ke Da Xue Xue Bao. 2023. PMID: 36856214 Free PMC article. Chinese.
-
lncRNA LOC102724169 plus cisplatin exhibit the synergistic anti-tumor effect in ovarian cancer with chronic stress.Mol Ther Nucleic Acids. 2021 Mar 5;24:294-309. doi: 10.1016/j.omtn.2021.03.001. eCollection 2021 Jun 4. Mol Ther Nucleic Acids. 2021. PMID: 33850634 Free PMC article.
-
Exploration of Potential Ewing Sarcoma Drugs from FDA-Approved Pharmaceuticals through Computational Drug Repositioning, Pharmacogenomics, Molecular Docking, and MD Simulation Studies.ACS Omega. 2022 Jun 1;7(23):19243-19260. doi: 10.1021/acsomega.2c00518. eCollection 2022 Jun 14. ACS Omega. 2022. PMID: 35721972 Free PMC article.
-
Characterisation of the Circulating Transcriptomic Landscape in Inflammatory Bowel Disease Provides Evidence for Dysregulation of Multiple Transcription Factors Including NFE2, SPI1, CEBPB, and IRF2.J Crohns Colitis. 2022 Aug 30;16(8):1255-1268. doi: 10.1093/ecco-jcc/jjac033. J Crohns Colitis. 2022. PMID: 35212366 Free PMC article.
References
-
- Xiao Q, Wei Z, Li Y, et al. miR‐186 functions as a tumor suppressor in osteosarcoma cells by suppressing the malignant phenotype and aerobic glycolysis. Oncol Rep. 2018;39(6):2703‐2710. - PubMed
-
- Huang L, Chen M, Pan J, Yu W. Circular RNA circNASP modulates the malignant behaviors in osteosarcoma via miR‐1253/FOXF1 pathway. Biochem Biophys Res Commun. 2018;500(2):511‐517. - PubMed
-
- Szu‐Ting C, Yi‐Ling L, Ming‐Ting H, et al. CLEC5A is critical for dengue‐virus‐induced lethal disease. Nature. 2008;453(7195):672‐676. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous